[Immunomodulation and neuroprotection in optic neuritis]

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Acute optic neuritis (ON) treatment primarily relies on high-dose corticosteroids.
• Corticosteroids do not prevent retinal nerve fiber loss in ON.
• There is a critical need for novel therapeutics to mitigate ganglion cell death in ON.

Purpose of the Study:

• To review current literature on immunomodulatory and neuroprotective drugs for acute optic neuritis (ON) treatment.
• To assess the potential of novel agents to reduce neuronal loss in ON.
• To identify emerging therapeutic strategies beyond corticosteroids.

Main Methods:

• Comprehensive literature search of clinical studies.
• Focus on treatments for optic neuritis (ON) using immunomodulatory and neuroprotective agents.
• Analysis of evidence for efficacy and impact on neuronal survival.

Main Results:

• Simvastatin (immunomodulatory) shows potential long-term benefits, particularly on visual evoked potentials.
• Memantine (neuroprotective) may positively impact retinal nerve fiber layer (RNFL) thickness.
• Erythropoietin demonstrated a reduction in RNFL thickness loss and is under extensive Phase III investigation. Results for phenytoin, amiloride, and anti-LINGO-1 are pending.

Conclusions:

• Emerging data suggest immunomodulatory and neuroprotective drugs offer hope for reducing neuronal loss in ON.
• Agents like simvastatin, memantine, and erythropoietin represent promising therapeutic avenues.
• Further research and clinical trials are essential to confirm the efficacy of these novel treatments for ON.